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Abstract 
Carnitine has key functions in energy metabolism. In most studies in animals or humans, 
carnitine supplementation did not influence muscle composition and function, but the effects 
of the carnitine esters acetylcarnitine or propionylcarnitine are not well characterized. We 
therefore investigated the influence of carnitine, acetylcarnitine and propionylcarnitine on 
body carnitine homeostasis, energy metabolism and physical performance in mice. Animals 
were orally supplemented with approximately 2 mmol/kg/d carnitine, acetylcarnitine or 
propionylcarnitine for four weeks, before being subjected to exhaustive exercise and analysis 
of skeletal muscle energy metabolism and morphology. 
In supplemented groups, the total plasma and urine carnitine concentrations were 
significantly higher than in the control group, whereas the skeletal muscle carnitine content 
remained unchanged. The bioavailability of supplemented carnitine or acylcarnitines was in 
the range of 20 to 23% as determined by urinary excretion of total carnitine. The 
supplemented acylcarnitines were hydrolyzed in the intestine and in the liver before reaching 
the systemic circulation. Skeletal muscle morphology including fiber type composition was 
not affected by treatment with carnitine or acylcarnitines. Oxygen consumption by muscle 
fibers obtained from soleus or gastrocnemius was not different between the groups. The 
supplementation of carnitine or acylcarnitines had no significant impact on the running 
capacity and on key substrates of skeletal muscle energy metabolism such as glycogen, 
ATP, phosphocreatine or creatine. 
In conclusion, oral supplementation of carnitine, acetylcarnitine or propionylcarnitine is 
associated with increased plasma concentrations of total carnitine and increased urinary 
excretion of carnitine, but does not affect the skeletal muscle carnitine content. Accordingly, 
physical performance, skeletal muscle energy metabolism, and muscle fiber type 
composition are not affected by high oral doses of carnitine or acylcarnitines in mice. 
 
Keywords: carnitine, acetylcarnitine, propionylcarnitine, skeletal muscle composition & 
metabolism, exercise
Introduction 
Carnitine is an amino acid derivative playing an essential role in cellular energy metabolism 
due to the acylation of its β-hydroxy group. The major carnitine pool, accounting for >95% of 
the total body stores, is in skeletal muscle (Krahenbuhl et al., 2000; Spaniol et al., 2001), 
where carnitine functions as a carrier of long-chain fatty acids (Fritz, 1955) and as a buffer of 
free coenzyme A (CoASH) (Brass et al., 1980; Friolet et al., 1994). 
Carnitine is an obligatory intermediate for the transport of long-chain fatty acids into the 
mitochondria. In order to reach the mitochondrial matrix for subsequent β-oxidation, long-
chain fatty acids have to be converted into the corresponding acyl-CoA and then into the 
acylcarnitine derivative. The second step is achieved by carnitine palmitoyltransferase 1 
(CPT1), the rate-limiting enzyme of β-oxidation (Roepstorff et al., 2005). As acylcarnitines, 
long-chain fatty acids are then transported across the inner mitochondrial membrane through 
the carnitine/acylcarnitine carrier (Indiveri et al., 2011) into the mitochondrial matrix. There, 
they enter β-oxidation after reconversion into the acyl-CoA derivative by CPT2 (Bremer, 
1983). 
During high intensity exercise, acetyl-CoA generated by pyruvate oxidation or by β-oxidation 
overwhelms the capacity of the Krebs cycle. Accumulating acetyl-CoA would rapidly deplete 
the limited CoA pool, if carnitine could not function as a buffer of the acetyl groups. Carnitine 
acetyltransferase converts acetyl-CoA to acetylcarnitine, thereby ensuring the availability of 
CoASH (Brass et al., 1980; Friolet et al., 1994). 
Taking into account these important functions of carnitine, it is not surprising that carnitine 
supplementation has been studied intensively as a potential performance enhancer (Brass, 
2004). In ex vivo models it has been reported that an elevation of the carnitine muscle 
content increases skeletal muscle force and delays fatigue (Brass et al., 1993; Dubelaar et 
al., 1991). In humans, most studies failed to show a positive effect of carnitine 
supplementation on physical performance, a finding correlating with the fact that the muscle 
carnitine content could not be increased by oral or parenteral carnitine supplementation 
despite elevated plasma concentrations (Brass, 2000). High oral doses of carnitine during 
several days or intravenous infusion for several hours before exercise failed to show an 
impact on the physical performance of healthy volunteers or athletes (Barnett et al., 1994; 
Oyono-Enguelle et al., 1988; Wachter et al., 2002). Recently, Wall and colleagues reported 
an approximately 20% increase of the carnitine muscle content in human subjects ingesting 
80 g carbohydrate and 2 g carnitine tartrate per day (Wall et al., 2011). This increase in the 
skeletal muscle carnitine content was associated with an enhanced work output, maintained 
skeletal muscle glycogen stores and a reduced production of lactate. 
In rodents, studies investigating the accumulation of carnitine in skeletal muscle associated 
with carnitine supplementation are controversial. An increase of the skeletal muscle carnitine 
content of supplemented animals was reported by several groups (Bacurau et al., 2003; 
Negrao et al., 1987), while in other investigations, no such increase could be detected 
(Lambert et al., 2009; Primassin et al., 2008). 
Whereas the dose und duration of carnitine supplementation seems to influence the carnitine 
accumulation in skeletal muscle of rodents, little is known about the effect of supplementation 
with carnitine derivatives, e.g. acetylcarnitine or propionylcarnitine, on the skeletal muscle 
carnitine content and physical performance. Elevated carnitine plasma concentrations are 
not necessarily associated with an increase in the skeletal muscle carnitine content due to 
saturation of the carnitine transport system into skeletal muscle at normal carnitine plasma 
concentrations (Berardi et al., 2000) and due to a large concentration gradient between 
plasma and skeletal muscle (Brass, 2000; Friolet et al., 1994). In comparison to carnitine, 
skeletal muscle concentrations of acetylcarnitine and propionylcarnitine are much lower 
under resting conditions. Similar to plasma, the acetylcarnitine concentration in skeletal 
muscle is in the range of 20% of the free carnitine concentrations (Friolet et al., 1994; Minkler 
et al., 2008), whereas, to the best of our knowledge, skeletal muscle propionylcarnitine 
concentrations have so far not been reported. A favorable gradient between plasma and 
skeletal muscle after supplementation could therefore facilitate transport of the amphiphilic 
acetyl- and propionylcarnitine into skeletal muscle by passive diffusion. 
In this study we therefore aimed to investigate the potential benefits of oral acetylcarnitine or 
propionylcarnitine supplementation on the skeletal muscle carnitine content and working 
capacity of mice and compare the findings with carnitine supplementation. After oral 
supplementation of carnitine or acylcarnitines during four weeks, mice were subjected to 
exhaustive exercise and the plasma and skeletal muscle carnitine pools as well as metabolic 
markers in muscle and plasma were analyzed. 
 
 
Material and methods 
Animals 
The experiments were performed in agreement with the guidelines for the care and use of 
laboratory animals and were approved by the cantonal veterinary authority (License 2509). 
The animals were adult male C57BL/6 mice (Janvier, Le Genest-Saint-Isle, France), housed 
in a standard facility with a 12h light-dark cycles and controlled temperature (21-22°C). The 
mice were fed with a standard pellet chow and water ad libitum. After seven days of 
acclimatization, the mice were divided into four groups of 12 animals each: 1) Control group 
(Ctrl), 2) Carnitine group (Cn), 3) Acetylcarnitine group (Acetyl-Cn), and 4) Propionylcarnitine 
group (Propionyl-Cn). Half of the animals of each group (n=6) were housed for 24 h in the 
metabolic cage and performed exhaustive exercise before sacrifice (see below). 
 
Carnitine or acylcarnitines supplementation 
L-carnitine and acetyl-L-carnitine HCl were purchased from Sigma (St. Louis, MO, USA). 
Propionyl-L-carnitine HCl was a kind gift of Sigma Tau (Pomezia, Rome, Italy). The solutions 
of carnitine, acetylcarnitine and propionylcarnitine were made in tap water once a week and 
were kept at 4°C until use. After one week of acclimatization, the mice were supplemented 
with carnitine, acetylcarnitine or propionylcarnitine via drinking water for 4 weeks. The 
concentration of carnitine and carnitine derivatives in tap water was 10 mmol/L so that mice 
of about 25 g drinking 5 mL/d would be exposed to approximately 2 mmol/kg/d of each 
compound. Water consumption was monitored daily. The carnitine content in the standard 
chow and in the drinking water was evaluated with a LC-MS/MS method previously 
described (Morand, 2012). 
 
Protocol 
Between week 1 and 2 of supplementation, the mice spent 24h individually in metabolic 
cages with supplemented water and food ad libitum. During this period, 24h urine was 
collected for the assessment of the excretion of carnitine and acylcarnitines. 
After 4 weeks of supplementation, the mice were submitted to an exhaustive exercise on a 
treadmill with previous acclimatization to the apparatus (Exer-3/6, Columbus Instruments, 
Columbus, OH, USA). Two days and one day before initiation of the study, each mouse 
underwent a five-minute training session at a speed of 5 m/min. On the day of sacrifice, the 
starting speed was 5 m/min; after 5 minutes, the speed was increased by 1 m/min every 
minute until the maximal speed of 20 m/min was reached. The rear of the treadmill was 
equipped with low-voltage, electric stimulating grids, to encourage the mice to run. The grid 
delivered 0.4 mA at a frequency of 2 Hz, which caused an uncomfortable shock without 
injuring the animal. Exhaustion was defined as immobility for more than 5 seconds on the 
end lane grid despite electric stimulation. 
The physical performance of the mice was calculated from the distance and the duration of 
the run according to the following equation: 
 
(1)  
 
with m being the mass of the animal, a the gravitational acceleration, d the run distance, and 
t the running time. 
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After exhaustion the mice were anaesthetized with an intraperitoneal application of ketamine 
(100 mg/kg) and xylazine (10 mg/kg). The soleus and the superficial part of the 
gastrocnemius muscles were excised and conserved in ice cold BIOPS buffer (10 mmol/L 
Ca-EGTA buffer, 0.1 μmol/L free calcium, 5.77 mmol/L ATP, 6.56 mmol/L MgCl2, 20 mmol/L 
taurine, 15 mmol/L phosphocreatine, 0.5 mmol/L dithiothreitol, and 50 mmol/L K-MES, pH 
7.1) until analysis. Blood was collected into heparin-coated tubes by an intracardiac puncture 
or a tail incision. Plasma was separated by centrifugation at 3000 g for 15 minutes. 
For chemical analysis muscle samples -red and white quadriceps biopsies- and liver samples 
were frozen in liquid nitrogen immediately after excision. Plasma, urine, liver and muscle 
samples were kept at -80°C until analysis. 
 
High resolution respirometry 
Mitochondrial respiration measured in situ allows the characterization of functional 
mitochondria in their normal intracellular position and assembly, preserving essential 
interactions with other organelles. Mitochondrial oxygen consumption was studied in 
saponin-skinned fibers (Kuznetsov, 2008). Fibers were separated under a binocular 
microscope in BIOPS buffer at 4°C. After dissection, fibers were transferred into BIOPS 
buffer containing 50 μg/mL saponin and incubated at 4°C for 30 minutes while shaking to 
complete permeabilization of the sarcolemma. Permeabilized fibers were then washed in 
BIOPS buffer for 10 minutes under intense shaking to completely remove saponin. Before 
oxygraphic measurements, the fibers were washed twice for 5 minutes in MiR05 buffer 
(EGTA 0.5 mmol/L, MgCl2 3 mmol/L, taurine 20 mmol/L, KH2PO4 10 mmol/L, HEPES 20 
mmol/L, D-sucrose 110 mmol/L, BSA essentially fatty acid free 1 g/L, and lactobionic acid 60 
mmol/L) to remove any trace amount of high-energy phosphates. All oxygen measurements 
were performed at 37°C with an Oxygraph 2k apparatus equipped with the Datlab software 
(OROBOROS, Innsbruck, Austria) (Pesta et al., 2012). Per respiration chamber, 1-2 mg of 
permeabilized fibers was added to 2.0 mL of MiR05 buffer. 
The following protocol was used to evaluate the activity of the different mitochondrial 
complexes. The rate of basal respiration was measured with the complex I substrates 
glutamate (10 mM) and malate (2 mM). Active respiration was induced with 2 mM ADP. After 
inhibition of complex I with 0.5 μM rotenone, the respiration was restored by addition of 
complex II substrate succinate (10 mM). Inhibition of complex II with 20 mmol/L malonate 
was followed by the addition of the artificial substrates for complex IV TMPD (0.5 mM) and 
ascorbate (2 mM). To verify the integrity of the outer mitochondrial membrane, cytochrome c 
(10 μmol/L) was added at the end of the respiration protocol. Respiration rates are expressed 
in picomoles O2 per second per gram wet weight. 
 
Histology 
Muscle biopsies for histological imaging were frozen in isopentane cooled in liquid nitrogen. 
Ten-micrometer serial sections were cut from the soleus and gastrocnemius muscle on a 
cryostat microtome (HYRAX C60, Carl Zeiss Microscopy, Jena, Germany) and mounted on 
glass slides. The histological structure of muscular fibers was determined by a routine 
hematoxylin/eosin staining. Soleus and gastrocnemius fiber type composition was 
determined by histochemical staining of the myosine ATPase activity (Bancroft 2008). 
Stained fibers at pH 9.4 were counted from two non-overlapping visual fields using a 
microscope (Olympus BX43, Olympus corporation, Tokyo, Japan) at a 100-fold 
magnification. Quantification was performed with an in-house software recognizing dark from 
light fibers. 
 
Urinary carnitine concentrations 
A LC-MS/MS method previously described was adapted for the determination of carnitine 
and acylcarnitines in urine (Morand, 2012). The method was extended to the analysis of 
propionylcarnitine (transitions 218/85 and 218/159) and creatinine (114/44 and 114/86). 
Hydrolysis of total carnitine was achieved with 0.5 mol/L potassium hydroxide, neutralization 
and dilution with 0.1% formic acid. 
 Plasma parameters 
Plasma concentrations of carnitine were determined as previously described with adaptation 
to propionylcarnitine (Morand, 2012). Venous lactate concentrations were analyzed with an 
enzymatic assay (Olsen, 1971). Creatine kinase activity in venous plasma was determined 
before and after exhaustive exercise with a kit according to the supplier’s instructions 
(BioAssay Systems, Hayward, CA, USA). 
 
Muscle and liver parameters 
Muscle tissue was homogenized with a Micro-dismembrator during 1 minute at 2000 rpm 
(Sartorius Stedim Biotech, Göttingen, Germany). 50 mg muscle was extracted with 1 mL of 
extracting solvent depending on the metabolites determined as described below. Liver tissue 
was homogenized during 30 seconds at 2000 rpm and then extracted with 1 mL methanol 
per 100 mg tissue. 
Phosphocreatine, creatine and ATP were determined photometrically in an acidic extract 
(perchloric acid 0.5 mol/L, EDTA 1 mmol/L) of muscle powder as described (Harris et al., 
1974). Muscle glycogen content was analyzed in alkaline (NaOH 0.1 mmol/L) muscle 
extracts according to Harris (Harris et al., 1974). Carnitine, acylcarnitines and total carnitine 
were determined in aqueous muscle extracts with an established LC-MS/MS (Morand, 2012). 
 
Statistical analysis 
Data is expressed as mean ± SEM. Statistical analyses were performed using unpaired two-
tailed Student’s t-test, one-way or two-way ANOVA followed by a Dunnett post-test with the 
software Prism version 5 (Graph Pad Software, San Diego, CA). Statistical significance was 
set at *p <0.05 and **p <0.01. 
 
 
Results 
Characterization of the animals 
During the study, food intake was similar in all groups and we observed no weight 
differences between the groups (Figure 1A). The daily water intake was increased in all 
groups treated with carnitine or acylcarnitines (p<0.05) compared to the control group (Figure 
1B). The control animals (n=12) drank 4.1 ± 0.2 mL/d, whereas the animals of the carnitine, 
acetylcarnitine and propionylcarnitine group ingested 5.2 ± 0.1 mL/d, 5.7 ± 0.3 mL/d, and 5.6 
± 0.1 mL/d, respectively (mean ± SEM; no difference between treated animals). The mean 
daily exposure to exogenous carnitine, acetylcarnitine or propionylcarnitine was 2.2 
mmol/d/kg (range 1.9-2.7 mmol/d/kg) in the treated groups and below 10 μmol/kg/d in the 
control group, taking into account the carnitine ingested in the drinking water and in the food 
(Figure 1C). The carnitine content of the food was 60 nmol/g. The concentrations of carnitine, 
acetylcarnitine, and propionylcarnitine in the drinking solutions remained stable during their 
storage at 4°C and in the water bottles at room temperature (data not shown). 
 
Carnitine and acylcarnitines pools in plasma, liver, and skeletal muscle and renal carnitine 
excretion 
In plasma, total carnitine concentrations were significantly higher in the treated groups 
compared to control (p<0.01 for Cn and Acetyl-Cn groups, p<0.05 for Propionyl-Cn) due to 
higher free carnitine concentrations (Table 1). Acetylcarnitine, propionylcarnitine, and 
palmitoylcarnitine plasma concentrations were similar between the groups. 
In liver samples of propionylcarnitine treated animals, carnitine and propionylcarnitine 
concentrations were significantly elevated (p<0.05) compared to control animals 
(Supplementary Table 2). 
In red or white skeletal muscle, we observed no difference in the carnitine pools between the 
groups treated with carnitine or acylcarnitines and the control group. The acetylcarnitine 
concentrations accounted for 20% of the total pool in red fibers and for 15% in the white 
fibers. Total carnitine, free carnitine, acetylcarnitine, and palmitoylcarnitine concentrations 
were by trend lower in the white compared to red quadriceps. Propionylcarnitine 
concentrations in skeletal muscle were below detection limits (<0.5 μM), also in mice treated 
with propionylcarnitine (Table 1). 
Treated animals excreted about 17 times more total carnitine than controls animals as 
reported in the supplementary Table 1. The excreted carnitine was found principally in the 
form of free carnitine and acetylcarnitine (Figure 2). In all treated groups, independently of 
the supplemented form of carnitine, the excretion of carnitine and acetylcarnitine was 
significantly higher (p<0.01) compared to control animals. Urinary excretion of 
propionylcarnitine could only be detected in the three supplemented groups, whereas the 
propionylcarnitine concentration was below the limit of detection in the urine of control mice. 
The highest urinary propionylcarnitine concentration was found in the propionylcarnitine 
group. Due to the high variability, this difference did not reach statistical significance between 
the treated groups (Supplementary Table 1). 
 
Carnitine balance under resting conditions 
Total carnitine ingestion and excretion in control and treated animals are presented in Table 
2. The total intake of carnitine was 200 times higher in animals supplemented with carnitine, 
acetylcarnitine or propionylcarnitine as compared to control animals. The carnitine tissue 
accumulation, which was calculated from the mean total carnitine concentration in red and 
white muscles and from the estimated muscle weight gain during the observation period of 
one month, was not different between the groups and was quantitatively negligible compared 
to oral ingestion of carnitine. Excretion of total carnitine was, as discussed above, 10 to 20 
times higher in the treated groups as compared to the control group. The carnitine balance, 
i.e. the difference between carnitine intake plus tissue accumulation and carnitine excretion, 
was negative in control mice and positive in all treated groups. The negative value in control 
mice mainly represents carnitine biosynthesis; the value is in agreement with reported values 
in rats assessed by a similar method (Krahenbuhl et al., 2000). The positive value in treated 
animals is mainly explained by incomplete bioavailability of carnitine and acylcarnitines. 
Bioavailability, as estimated from carnitine ingestion and urinary excretion, ranged between 
20% and 23% without a difference between the groups supplemented with carnitine. 
 
High resolution respirometry 
As expected, the maximal respiration rate in the soleus muscle, which is mainly composed of 
oxidative fibers, was higher than in the gastrocnemius, which consists mainly of glycolytic 
fibers. For the soleus and the gastrocnemius muscle biopsies, we observed no significant 
difference in oxygen uptake for the different conditions tested between the groups. These 
findings indicate that mitochondrial content and capacity remained unchanged in the 
supplemented compared to the control group (Figure 3).  
 
Histology 
As reported in Figure 4, we observed no difference in the muscle fiber type composition in 
the soleus and gastrocnemius muscles of treated as compared to control animals. In soleus 
muscle, type I fibers represented about 70% of the fibers in all the groups studied (Fig. 4B). 
 
Exhaustive exercise 
As shown in Figure 5, the mean running distance until exhaustion of untreated mice was 561 
± 150 m (n=6). The distance covered by treated mice was by trend increased in all the 
groups but no statistical significance was observed because of high interindividual variability 
(carnitine 699 ± 265 m, acetylcarnitine 772 ± 320 m, propionylcarnitine 820 ± 525 m). The 
performance of the animals was in the range of 67 – 69 mW and was not different between 
the groups. 
 
Energy parameters in plasma and skeletal muscle in resting mice and mice after exhaustive 
exercise 
As shown in Table 3, plasma lactate levels increased significantly with exercise in all the 
groups (p<0.01). By trend, lactate concentrations after exercise were lower in the three 
supplemented groups as compared to the control group, though not reaching statistical 
significance. Creatine kinase activity was not different between supplemented and control 
animals and showed a slight elevation with exercise compared to resting conditions (results 
not shown). 
Energy parameters were determined in separate samples of white and red quadriceps 
femoris (Table 3). The creatine and phosphocreatine concentrations were not different 
between supplemented and control groups and were not significantly influenced by exercise. 
Similarly, the skeletal muscle ATP content was not affected by exercise. There were no 
significant differences between control and supplemented groups, although there was a trend 
for a higher ATP content in red fibers from supplemented mice. The glycogen content was 
higher in white skeletal muscle fibers compared to red fibers. After exercise, a significant 
decrease of the glycogen content was observed in white fibers, while no difference was 
noticed in red fibers. The glycogen content after exercise was by trend higher in treated 
groups, but again without reaching statistical difference. 
 
 
Discussion 
In the current study we investigated the effects of an oral supplementation of carnitine, 
acetylcarnitine, or propionylcarnitine on the body carnitine balance, skeletal muscle 
composition and exercise capacity of mice. We could show that carnitine, acetylcarnitine, 
and propionylcarnitine supplementation did not influence the skeletal muscle carnitine pool 
when administered orally for 4 weeks at a dose of 2 mmol/kg/d. Accordingly, acetylcarnitine 
or propionylcarnitine administered orally had no significant impact on skeletal muscle 
composition or physical performance. 
Other animal studies also reported that there is no impact of carnitine supplementation on 
the skeletal muscle carnitine content. In rats, low oral doses of carnitine or acetylcarnitine 
(200 μmol/kg/d) for 14 days did not increase the skeletal muscle carnitine pool (Lambert et 
al., 2009). In mice, a higher carnitine dose (200 mg/kg/d or approximately 1 mmol/kg/d) for 
five weeks also failed to show an effect on the skeletal muscle carnitine pool (Primassin et 
al., 2008). To the best of our knowledge, such data were so far lacking for propionylcarnitine. 
The few animal studies performed in rats or mice reporting a positive effect of carnitine 
supplementation on the skeletal muscle carnitine pool either used high parenteral doses 
during a relatively long period of time (4 mmol/kg/d during 8 weeks) (Negrao et al., 1987) or 
determined the carnitine content only in soleus muscle (Bacurau et al., 2003). In our study, 
we could not confirm this finding in deep quadriceps biopsies, which mainly contain red fibers 
similar to the soleus muscle. In agreement to our findings, supplementation of high doses of 
carnitine or acylcarnitines had no influence on the muscle fiber type composition also in other 
studies (Cassano et al., 2010). This is in agreement with our observation that treatment with 
carnitine or acylcarnitines had no significant impact on the oxygen consumption profiles by 
skeletal muscle fibers. 
Similar to our study, also most studies in humans failed to show an impact of carnitine 
supplementation on total muscle carnitine content and on physical performance (Barnett et 
al., 1994; Wachter et al., 2002). Recently, however, increased carnitine skeletal muscle 
concentrations in humans treated with high amounts of carbohydrates to induce 
hyperinsulinemia have been reported (Wall et al., 2011). It was hypothesized that insulin 
enhances carnitine transport via stimulation of the Na+/K+ ATPase, leading to the formation of 
a higher Na+ gradient to drive the sodium-dependent carnitine transporter OCTN2. In a 
similar study, a higher expression of OCTN2 five hours after an infusion of carnitine and 
insulin was demonstrated, offering a second possible explanation for the observed increase 
in the skeletal muscle carnitine content under hyperinsulinemic conditions (Stephens et al., 
2006). In the study of Wall et al. the increase of the skeletal muscle carnitine content was 
observed only in the group treated for 24 weeks and not in the group treated for 12 weeks, 
suggesting that long supplementation periods are required to increase the muscle carnitine 
pool (Wall et al., 2011). In this context, it has to be pointed out that the transport mechanisms 
of carnitine into skeletal muscle are not fully characterized. It is well established that the 
sodium-dependent carnitine carrier OCTN2 is expressed in skeletal muscle (Nezu et al., 
1999; Spaniol et al., 2001; Stephens et al., 2006; Tamai et al., 1998; Tamai et al., 2000). On 
the other hand, the study of Berardi et al. (Berardi et al., 2000) using rat skeletal muscle 
membrane vesicles revealed carnitine transport characteristics which are not completely 
compatible with the properties of OCTN2. It is therefore currently unclear whether the 
transport of carnitine into skeletal muscle can fully be explained by OCTN2 or whether 
additional carnitine carriers exist. 
After exercise, we did not observe significant differences in the skeletal muscle 
phosphocreatine content compared with resting conditions, suggesting that exercise was not 
intensive enough, although the mice were exhausted according to our criteria. Exhaustive 
exercise is supported, however, by the observed increase in the plasma lactate 
concentrations in exercising mice and in the decrease of the glycogen content in skeletal 
muscle. Even though the interval between end of exercise and sacrifice of the mice was in no 
case longer than 15 minutes, this period may have been long enough to allow an at least 
partial recovery of the phosphocreatine pool. 
In mice, the bioavailability of low doses of carnitine (250 ng/kg) was reported to be 67% 
(Yokogawa et al., 1999), which is clearly higher than the values found in the current study. 
For acetylcarnitine and propionylcarnitine, the absorption profile in mice is not known. In 
humans, although it was suggested that acetylcarnitine is partly hydrolyzed in enterocytes, 
oral doses of acetylcarnitine increased the corresponding plasma concentrations by 40% 
(Rebouche, 2004). The bioavailability of propionylcarnitine has not been determined 
specifically in mice, but has been estimated to be less than 20% (Mancinelli et al., 2005). Our 
study was not designed as a pharmacokinetic study, but nevertheless allowed to estimate 
some kinetic parameters of the administered compounds. As shown in Table 2, the 
bioavailability of carnitine with carnitine, acetylcarnitine or propionylcarnitine is in the range of 
20 – 24% irrespectively of the compound administered and based on urinary excretion of 
carnitine after oral ingestion of the compounds. The comparison with the study of Yokogawa 
et al. therefore suggests that carnitine absorption is concentration-dependent (Yokogawa et 
al., 1999). Furthermore, the current study indicates that orally ingested acylcarnitines 
undergo hydrolysis both in the intestinal tract and in the liver. This interpretation is based on 
our findings that we did not observe increased concentrations of acylcarnitines in the 
systemic circulation and that we found elevated concentrations of carnitine and 
propionylcarnitine in the liver after oral ingestion of propionylcarnitine. 
As mentioned above, the supplemented carnitine, acetylcarnitine or propionylcarnitine were 
excreted mainly as carnitine and to a lesser extent as acetylcarnitine, independently of the 
supplemented carnitine derivative. Whereas propionylcarnitine was below the limit of 
quantification in the urine of control mice, it was present in the urine of all treated animals, 
also of the mice supplemented with carnitine or acetylcarnitine. Similarly, in humans treated 
with oral carnitine, elevated concentrations of acetylcarnitine and propionylcarnitine have 
been observed in plasma and urine (Cao et al., 2009). Furthermore, in patients with end-
stage renal failure undergoing hemodialysis, intravenous administration of carnitine was 
associated with increased plasma concentrations of many acylcarnitines and increased 
elimination of acylcarnitines by dialysis (Vernez et al., 2006). These findings suggest that the 
circulating plasma carnitine exchanges with tissue where it can acylated, transported back 
into plasma and eventually be excreted via the urine. 
In conclusion, oral supplementation of carnitine, acetylcarnitine or propionylcarnitine was 
associated with increased plasma concentrations of total carnitine and increased urinary 
excretion of carnitine, but did not affect the skeletal muscle carnitine content. Accordingly, 
physical performance and skeletal muscle energy metabolism were not affected by carnitine 
supplementation. Further studies assessing the effect of acylcarnitines on the skeletal 
muscle carnitine content and physical performance would have to be carried out with 
parenteral administration, thus circumventing precocious hydrolysis. 
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Figures legends 
 
Figure 1 
Characterization of the animals. The weight gain (in grams) was similar in the treatment 
groups compared to control (A). Water consumption (in mL/mouse/d) was significantly higher 
in the treated groups (B). Daily consumption of carnitine or acylcarnitines was below 10 
μmol/kg/d in the control group and in the range of 2000 μmol/kg/d in the supplemented 
groups (C). Data is represented as mean ± SEM of 12 animals per group. 
 
Figure 2 
Mean urinary excretion of carnitine, acetylcarnitine and total carnitine. Mice supplemented 
with carnitine, acetylcarnitine or propionylcarnitine excreted significantly higher amounts of 
carnitine and acetylcarnitine than the control group. Data is expressed as mmol/kg/d (mean ± 
SEM of 6 animals per group) 
 
Figure 3 
Oxygen consumption of isolated muscle fibers. We observed no differences between 
carnitine or acylcarnitine supplemented mice and control mice. Data is represented as mean 
in pmol O2/s/mg protein ± SEM of six animals. 
 
Figure 4 
Histochemical determination of muscle fibers composition. (A) Representative ATPase and 
hematoxylin/eosin (H/E) staining of soleus and gastocnemius (GC) biopsies. (B) In soleus 
muscle we observed no difference in muscle fibers composition between treated and control 
animals. Mean values ± SEM of six animals are represented. 
 
Figure 5 
Running capacity of mice completing a treadmill exercise until exhaustion. We observed a 
slight upward trend for the running distance (A) in treated groups. Performance expressed in 
mW (B) did not differ between the groups. Mean values ± SEM of six animals are 
represented. 
  
Table 1 
Carnitine and acylcarnitines concentrations in plasma and skeletal muscle under resting 
conditions. Mean values ± SEM of six animals are represented. **: p<0.01 compared to 
control, * p<0.05 compared to control. 
 Control Carnitine Acetylcarnitine Propionylcarnitine 
Plasma concentrations (μmol/L) 
Carnitine 31.0±0.5 37.2±2.2 36.1±1.4 35.6±3.4 
Acetylcarnitine 7.8±0.8 8.5±1.3 9.3±0.6 7.6±0.7 
Propionylcarnitine 0.30±0.04 0.24±0.07 0.27±0.04 0.76±0.38 
Palmitoylcarnitine 0.25±0.01 0.29±0.04 0.25±0.02 0.30±0.03 
Total carnitine 36.4±1.4 47.7±1.8** 47.6±1.6** 42.7±1.6* 
Skeletal muscle concentrations (µmol/kg wet weight) 
Red quadriceps  
Free carnitine 205±29 272±32 216±25 189±14 
Acetylcarnitine 66±7 69±11 70±3 62±9 
Propionylcarnitine <0.5 <0.5 <0.5 <0.5 
Palmitoylcarnitine 44±8 55±6 32±12 28±5 
Total carnitine 291±31 309±59 359±56 249±43 
White quadriceps  
Free carnitine 110±7 115±10 127±11 130±11 
Acetylcarnitine 39±5 37±10 26±3 28±5 
Propionylcarnitine <0.5 <0.5 <0.5 <0.5 
Palmitoylcarnitine 15±5 20±3 14±3 19±5 
Total carnitine 195±17 207±14 169±20 152±14 
 
  
Table 2 
Total carnitine balance under resting conditions. Intake by water and food was determined as 
described in Methods. Carnitine tissue accumulation was calculated based on the carnitine 
content in skeletal muscle and the estimated increase in skeletal muscle weight. Carnitine 
excretion was determined in 24-hour urines of the animals. The carnitine balance was 
calculated as the difference between carnitine intake plus tissue accumulation and carnitine 
excretion. Values are given as µmol/kg/d ± SEM. 
 
Treatment group (n = 6) Intake 
Tissue 
accumulation Excretion Balance 
 Water Food    
Control 0±0 0.32±0.06 9.5±0.1 31±4 -22±4 
Carnitine 2072±27 0.40±0.10 9.6±0.2 472±152 1609±155 
Acetylcarnitine 2254±114 0.30±0.06 9.6±0.2 451±80 1812±140 
Propionylcarnitine 2259±48 0.44±0.08 9.6±0.2 501±40 1767±63 
 
  
Table 3 
Effect of exercise on skeletal muscle and plasma parameters. Mean values ± SEM of six 
animals are presented. ** p<0.01 compared to resting values, * p<0.05 compared to resting 
values. There were no significant differences between control and carnitine or acylcarnitines 
treated animals.  
 CTRL Cn Acetyl-Cn Propionyl-Cn 
 CTRL Cn Acetyl-
Cn 
Propionyl-
Cn 
  Red quadriceps 
 Resting conditions  Exhaustive exercise 
Creatine 
(μmol/kg w.w.)  25.4±1.5 23.6±1.3 28.2±0.8 25.2±2.1  25.8±1.2 26.6±1.3 24.8±1.8 28.3±1.4 
Phosphocreatine 
(μmol/kg w.w.) 3.1±1.2 7.5±1.8 7.1±1.0 6.1±1.8  4.4±1.1 7.7±1.8 5.5±1.4 7.0±1.2 
ATP 
(μmol/kg w.w.) 4.3±0.6 8.6±1.7 9.9±0.9 8.5±1.4  6.6±1.2 11.0±1.6 8.8±1.0 9.3±1.2 
Glycogen 
(mmol/kg w.w.) 9.5±1.2 11.8±1.0 12.8±1.0 11.5±2.9  7.3±1.7 14.7±2.3 11.1±0.8 8.5±1.9 
  White quadriceps 
 Resting conditions  Exhaustive exercise 
Creatine 
(μmol/kg w.w.)  23.7±2.5 21.8±2.5 21.8±2.3 21.6±1.5  26.1±2.0 26.1±1.4 23.0±2.1 24.5±1.2 
Phosphocreatine 
(μmol/kg w.w.) 11.8±2.0 12.1±0.4 10.9±2.5 10.3±2.0  8.1±1.3 7.7±2.2 12.1±0.9 9.3±1.3 
ATP 
(μmol/kg w.w.) 8.2±1.0 9.7±1.0 9.6±0.6 9.2±0.9  9.4±1.0 9.1±2.0 10.9±1.1 9.3±0.7 
Glycogen 
(mmol/kg w.w.) 17.0±2.9 13.6±1.5 20.9±1.7 15.1±1.4  5.6±2.0* 9.7±1.4 11.3±1.1* 12.6±2.5 
  Plasma 
 Resting conditions  Exhaustive exercise 
Lactate 
(mmol/L) 2.2±0.2 2.2±0.2 2.1±0.2 1.9±0.1  6.2±0.5** 4.8±0.3** 5.0±0.2** 5.2±0.5** 
 
Supplementary Table 1 
Urinary excretion of carnitine, acetylcarnitine (Acetyl-Cn), propionylcarnitine (Propionyl-Cn), 
and total carnitine. Excreted amounts are mean values ± SEM of six animals, given in 
μmol/kg/d. **: p<0.01 compared to control group. 
 CTRL Carnitine Acetyl-Cn Propionyl-Cn 
Free carnitine 19±2 356±71** 335±68** 360±34** 
Acetylcarnitine 2±0 41±10** 54±13** 46±6** 
Propionylcarnitine <0.5 1.0±0.3** 1.1±0.3** 3.3±1.1** 
Total carnitine 24±4 417±143** 390±76** 448±36** 
 
 
  
Supplementary Table 2 
Liver concentrations of carnitine, acetylcarnitine and propionylcarnitine. Values ± SEM of six 
animals of the control and propionylcarnitine (Propionyl-Cn) groups are given in μmol/kg wet 
weight. * p<0.05 compared to control group. 
 
 CTRL Propionyl-Cn 
Free carnitine 314±16 449±46* 
Acetylcarnitine 195±8 231±22 
Propionylcarnitine 3.1±0.2 4.7±0.5* 
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